Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2021-11-16 AGM Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Annual General Meeting - Conference Link 2 pages 170.1KB
AGM Information Classification · 95% confidence The document is an announcement reminding shareholders about the upcoming Annual General Meeting (AGM) of PYC Therapeutics, including details on the date, time, location, and how to access the meeting via a conference link. It does not contain the actual AGM materials, minutes, or presentations but rather provides logistical information for attending the AGM. The document length is 3729 characters, which is relatively short and consistent with an announcement rather than a full report. There is no financial data, voting results, or detailed report content included. Therefore, this document fits the category of AGM Information (AGM-R), as it is related to the AGM event itself and the information shared for participation.
2021-11-16 English
Successful Completion of Key Translational Milestone 4 pages 196.8KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated November 2021 from PYC Therapeutics describing the successful completion of a key translational milestone in non-human primates for their RNA drug candidate. It details preclinical study results, safety and tolerability data, and outlines next steps towards clinical trials. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The content is a corporate update on drug development progress, typical of a Capital/Financing Update or general corporate announcement. It is not a report publication announcement since it contains substantive study data and analysis rather than just announcing a report release. It is not a regulatory filing or legal proceeding update. The focus on drug development milestones and preclinical study results aligns best with Capital/Financing Update (CAP) as it relates to progress in the company's pipeline and potential future financing implications. Confidence is high given the detailed scientific and developmental content and absence of financial reporting.
2021-11-15 English
Trading Halt 3 pages 192.6KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from PYC Therapeutics Limited regarding a request for a trading halt on its securities pending an upcoming announcement about Non-human Primate tolerability and safety results. The text explicitly states that the trading halt is requested under ASX Listing Rule 17.1 and that the halt will be lifted upon release of the announcement. There is no financial data, report, or detailed analysis included in this document. It is a short notice primarily about the trading halt and the pending announcement, not the announcement itself or a financial report. Given the document length (4337 characters) and content, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and compliance document rather than a financial report or other specific filing type.
2021-11-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 245.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'REPORT FOR THE QUARTER ENDED 30 SEPTEMBER 2021 (Q3)' and contains detailed financial data including a consolidated statement of cash flows for the quarter and year-to-date periods. It also includes operational updates, progress on drug development, and payments to related parties. The presence of detailed financial statements and analysis for a quarter indicates this is a comprehensive interim or quarterly report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-10-27 English
Notice of Annual General Meeting/Proxy Form 17 pages 1.1MB
AGM Information Classification · 100% confidence The document is titled '2021 Annual General Meeting' and contains detailed information about the upcoming AGM, including the date, location, agenda, resolutions to be voted on, and instructions for shareholders. It includes a Notice of Annual General Meeting, an Explanatory Statement, and proxy voting details. The document references the Annual Report for the financial year ended 30 June 2021 but does not contain the report itself. It also includes resolutions related to the Remuneration Report and re-election of directors, typical for AGM materials. The document is comprehensive and clearly intended as the official AGM information and materials shared with shareholders to prepare for the meeting. Therefore, it fits the category of AGM Information (AGM-R).
2021-10-18 English
Retina Target Engagement Confirmed in Large Eye 3 pages 315.1KB
Regulatory Filings Classification · 95% confidence The document is a press release dated September 28, 2021, from PYC Therapeutics announcing non-GLP study results about their RNA drug candidate's ability to penetrate the retina. It discusses preclinical study outcomes, upcoming clinical trials, and the company's technology platform. There are no financial statements, regulatory certifications, or detailed financial data. The document is an update on research progress and company development rather than a formal financial or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about scientific progress and company status, which aligns best with a Regulatory Filings (RNS) classification as a general regulatory announcement or corporate update that does not fit other specific categories.
2021-09-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.